In:
Blood Advances, American Society of Hematology, Vol. 3, No. 21 ( 2019-11-12), p. 3266-3277
Kurzfassung:
The cost of TKI for treatment of CML can be substantially saved by treatment discontinuation in patients who achieved DMR. Starting treatment with imatinib is the most cost-effective strategy even after incorporation of treatment discontinuation.
Materialart:
Online-Ressource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2019000745
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2019
ZDB Id:
2876449-3
Permalink